Ticker Story
COGT
Cogent Biosciences, Inc.
2 independent mixed-direction signals · 19 days
2 of 8 signal types active in the last 90 days
AI Analysis
COGT is displaying convergence across two independent signal sources—a recent trademark filing and fund position activity—that are providing mixed directional indicators as of 19 days ago.
Signal Timeline
KITVI (BEZUCLASTINIB) TABLETS — Pharmaceutical preparations for the treatment of systemic mastocytosis and gastrointestinal stromal tumors mediated by a c-kit or mutant c-k
View primary source →KITVAY (BEZUCLASTINIB) TABLETS — Pharmaceutical preparations for the treatment of systemic mastocytosis and gastrointestinal stromal tumors mediated by a c-kit or mutant c-k
View primary source →Citadel Advisors — decrease position (-43%) · $41.5M
View primary source →Point72 Asset Management — decrease position (-47%) · $28.8M
View primary source →Renaissance Technologies — increase position (+42%) · $38.6M
View primary source →Vanguard Capital Management — 13G, 5.08% of Cogent Biosciences Inc
View primary source →COGENT CONNECT — Educational services, namely, conducting patient education programs in the field of disease management; Providing a website featuring educat
View primary source →BlackRock, Inc. — 13G/A, 8% of Cogent Biosciences, Inc.
View primary source →Deerfield Mgmt, L.P. — 13G/A, 5.29% of Cogent Biosciences, Inc.
View primary source →Fairmount Funds Management LLC — 13D/A, 8.6% of Cogent Biosciences, Inc.
View primary source →The Vanguard Group — 13G/A, 0% of Cogent Biosciences Inc
View primary source →Kynam Capital Management, LP — 13G/A, 4.33% of Cogent Biosciences, Inc.
View primary source →Commodore Capital LP — 13G/A, 1.8% of Cogent Biosciences, Inc.
View primary source →The Vanguard Group — 13G/A, 7.5% of Cogent Biosciences Inc
View primary source →Fairmount Funds Management LLC — 13D/A, 9.9% of Cogent Biosciences, Inc.
View primary source →BlackRock, Inc. — 13G/A, 6.5% of Cogent Biosciences, Inc.
View primary source →BlackRock, Inc. — 13G/A, 6.5% of Cogent Biosciences, Inc.
View primary source →Fairmount Funds Management LLC — 13D/A, 9.9% of Cogent Biosciences, Inc.
View primary source →TCG Crossover GP I, LLC — 13G/A, 4.8% of Cogent Biosciences, Inc.
View primary source →Kynam Capital Management, LP — 13G/A, 5.54% of Cogent Biosciences, Inc.
View primary source →Paradigm BioCapital Advisors LP — 13G/A, 2.3% of Cogent Biosciences, Inc.
View primary source →Point72 Asset Management, L.P. — 13G/A, 4% of Cogent Biosciences, Inc.
View primary source →Commodore Capital LP — 13G/A, 7.2% of Cogent Biosciences, Inc.
View primary source →Commodore Capital LP — 13G, 5.5% of Cogent Biosciences, Inc.
View primary source →Venrock Healthcare Capital Partners II, L.P. — 13G/A, 4.2% of Cogent Biosciences, Inc.
View primary source →Commodore Capital LP — 13G/A, 4.6% of Cogent Biosciences, Inc.
View primary source →Paradigm BioCapital Advisors LP — 13G/A, 9.1% of Cogent Biosciences, Inc.
View primary source →⚠ Detection and context from official public sources — not financial advice, not a prediction.